je.st
news
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
2013-04-29 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & NEW YORK WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (Merck), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizers ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Language: English Contact HTML: Merck Media Relations:Steven Cragle: (908) 423-3461Kim Hamilton: (908) 423-6831orPfizer Media Relations:Joan Campion: (212) 733-2798orMerck Investor Relations:Carol Ferguson: (908) 423-4465Justin Holko: (908) 423-5088orPfizer Investor Relations:Chuck Triano: (212) 733-3901 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
Tags: for
type
enter
agreement
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||